CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-03-11): Bristol-Myers hepatitis drug impressive - US panel

Regulatory

Bristol-Myers hepatitis drug impressive - US panel

Last Updated: 2005-03-11 16:16:01 -0400 (Reuters Health)

GAITHERSBURG, Md. (Reuters) - U.S. health experts on Friday praised the effectiveness of Bristol-Myers Squibb Co.'s experimental hepatitis B drug and recommended the Food and Drug Administration approve it to treat the disease in adults.

The advisory panel voted unanimously to support the drug, entecavir, saying data showed it was superior to other available medicines.

The FDA usually follows the advice of its advisory panels.

"I'm impressed by what I've seen today," said panelist Lynn Paxton of the Centers for Disease Control and Prevention.

Company officials told the panelists that data from clinical trials showed entecavir was more potent than other approved hepatitis drugs, including GlaxoSmithKline Plc's Epivir and Gilead Sciences Inc.'s Hepsera.

It was also stronger than rival hepatitis drug telbivudine, which is being developed by Novartis AG and Idenix Pharmaceuticals Inc., Bristol officials said.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.